melanoma helper peptide vaccine

BIOLOGICAL2 trials

Sponsors

Eastern Cooperative Oncology Group, Craig L Slingluff, Jr

Conditions

Melanoma (Skin)

Phase 1

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

CompletedNCT00118274

Craig L Slingluff, JrMelanoma (Skin)

Start: 2005-03-31End: 2010-02-28Updated: 2021-04-20

Phase 2

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

CompletedNCT00071981

Eastern Cooperative Oncology GroupMelanoma (Skin)

Start: 2005-05-09End: 2014-01-31Updated: 2023-06-28

Related Papers

Adverse Events as a Function of Biological Sex in a Multicenter Clinical Trial of Melanoma Vaccines

Cancers2024-11-201 citations

Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial.

2024-03-2220 citations

Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma

Journal for ImmunoTherapy of Cancer2021-08-0158 citations